02 / The technology
Selective affinity. Simple workflow.
HemoDefend uses proprietary affinity technology to selectively bind anti-A and anti-B antibodies while allowing the blood product to pass through.
Step 01
Collect
Standard collection of platelets, plasma or whole blood. HemoDefend is designed for routine use in blood centers prior to storage.
Step 02
Filter with HemoDefend
Anti-A and anti-B antibodies bind to the affinity media; the product flows through.
Step 03
Low-titer, broadly compatible product
Ready to enter a simplified, more interchangeable inventory.
- Gravity-driven, 5–10 minutes per unit
- No capital equipment
- Designed to fit into existing workflows
- Reduces anti-A and anti-B antibodies to low-titer levels
- Preserves blood-product quality and volume
03 / Platform
One technology. Multiple blood products.
The same core affinity technology addresses ABO antibody compatibility across the blood ecosystem. Platelets are the initial intended commercial focus, subject to successful development and regulatory authorization; plasma, whole blood and plasma processing are additional platform opportunities.
Initial commercial focus
Platelets
Extensively evaluated
Plasma
Evaluated
Whole blood
Longer-term opportunity
Plasma processing
Potential future
Freeze-dried plasma
Military & emergency medicine
International blood systems
04 / Why it matters
Less fragmentation. More flexibility.
The intended operational benefits of low-titer, broadly compatible products. These remain development objectives, not established outcomes.
01
Greater interchangeability
Of blood products across ABO types.
02
Simplified inventory
Less blood-type-specific stocking to manage.
03
Easier allocation & redistribution
Move product where it is needed.
04
Reduced type-specific dependence
Fewer constraints tied to individual ABO groups.
05
Flexibility in shortages
And during emergencies.
06
Fewer ABO-non-identical transfusions
Potential reduction in ABO-non-identical product use.
09 / Partner with us
Build the next stage with us.
We welcome discussions with blood centers, strategic partners, plasma processors, potential investors and biomedical collaborators on:
Blood-center collaboration
Strategic partnerships
Research & development
Plasma-processing applications
Investment
Business development
Send an inquiry
Form goes here. Replace this note with your form block (WPForms or Gravity Forms). Suggested fields: Name, Organization, Email, Inquiry type, Message. The theme styles the fields automatically.